INVO Fertility Inc(IVF) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:30 PM ET (Korea 9/12 08:30)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -30.76 | Insider Own | 12.11% | Shs Outstand | 2.3M | Perf Week | -1.45% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 2.2M | Perf Month | -4.05% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 6.3% | Short Float | 16.71% | Perf Quarter | -34.96% |
| Income | -0.01B | P/S | 0.32 | EPS this Y | - | Inst Trans | -9.47% | Short Ratio | 0.09 | Perf Half Y | -76.28% |
| Sales | 0.01B | P/B | 0.14 | EPS next 5Y | - | ROA | -26.06% | Short Interest | 0.37M | Perf YTD | -74.25% |
| Book/sh | 7.01 | P/C | 0.65 | EPS past 3/5Y | 86.33% 72.72% | ROE | -61.53% | 52W High | -98.85% ($84.40) | Perf Year | -97.62% |
| Cash/sh | 1.49 | P/FCF | - | Sales past 3/5Y | 102.64% 45.83% | ROIC | -31.16% | 52W Low | 7.67% ($0.90) | Perf 3Y | -99.95% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 99.18% | Gross Margin | 27.82% | Volatility(W/M) | 3.53% 12.32% | Perf 5Y | -100% |
| Dividend TTM | - | EV/Sales | 0.4 | Sales Y/Y TTM | 13.76% | Oper. Margin | -78.72% | ATR (14) | 0.11 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 0.67 | EPS Q/Q | 100.09% | Profit Margin | -78.11% | RSI (14) | 42.78 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.71 | Sales Q/Q | 16.73% | SMA20 | -9.2% ($1.07) | Beta | 2.38 | Target Price | $20 |
| Payout | - | Debt/Eq | 0.24 | Earnings | 2026/8/17 | SMA50 | -10.12% ($1.08) | Rel Volume | 0.01 | Prev Close | $0.96 |
| Employees | 42 | LT Debt/Eq | 0.14 | EPS/Sales Surpr. | - | SMA200 | -70.08% ($3.24) | Avg Volume(3M) | 4.23M | Price | $0.97 |
| IPO | 2008/11/11 | Option/Short | No/Yes | Trades | 386 | Volume | 54,157 | Change | 0.53% |
Company
IVF is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
(INVO Fertility) is a Nasdaq-listed healthcare company in the U.S. focused on infertility treatment. It operates two core business lines: directly running INVO Center clinics, which offer intravaginal culture (IVC) procedures using its proprietary medical device INVOcell, as well as conventional in vitro fertilization (IVF) clinics; and selling and distributing the INVOcell device to third-party clinics.
Over the past 1 year, on the lower side
99% below its 1-year high.
IVF has weak earning power
Review management risk carefully before investing
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 1 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -100.0% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 6.3%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $2M.
IVF $2M PER -
ABT $176B PER 33.0
MDT $116B PER 22.4
SYK $106B PER 28.6
FAQ
What kind of company is IVF?
IVF belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of IVF?
The market cap of IVF is approximately $2M, ranking 5,826 within its sector.
What is the 52-week high and low for IVF?
IVF has recorded a 52-week high of $84.40 and a low of $0.90.
